Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
---|---|---|---|---|---|---|
Income Statement | ||||||
Total Revenue | 187.64M | 131.16M | 0.00 | 0.00 | 0.00 | 0.00 |
Gross Profit | 176.42M | 125.88M | -383.00K | -531.00K | -199.00K | -155.00K |
EBITDA | -110.08M | -217.27M | -206.06M | -141.65M | -72.56M | -43.66M |
Net Income | -95.00M | -95.50M | -188.92M | -132.18M | -70.44M | -40.51M |
Balance Sheet | ||||||
Total Assets | 519.04M | 582.79M | 376.05M | 349.06M | 289.82M | 45.66M |
Cash, Cash Equivalents and Short-Term Investments | 453.10M | 531.72M | 366.35M | 342.27M | 284.31M | 43.73M |
Total Debt | 3.00M | 2.60M | 408.00K | 813.00K | 220.00K | 402.00K |
Total Liabilities | 58.20M | 80.04M | 29.51M | 17.02M | 8.67M | 94.16M |
Stockholders Equity | 460.83M | 502.75M | 346.54M | -269.67M | -127.49M | -54.20M |
Cash Flow | ||||||
Free Cash Flow | -120.52M | -80.28M | -150.08M | -109.90M | -56.54M | -13.58M |
Operating Cash Flow | -63.06M | -78.11M | -146.85M | -109.87M | -48.54M | -13.49M |
Investing Cash Flow | -343.63M | -230.99M | 128.38M | -255.07M | -8.00M | -92.00K |
Financing Cash Flow | 202.69M | 203.29M | 164.00M | 165.90M | 297.12M | 29.98M |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
---|---|---|---|---|---|---|---|
62 Neutral | $810.84M | ― | -43.63% | ― | ― | -13.05% | |
60 Neutral | $1.07B | ― | -19.89% | ― | 95.94% | 35.69% | |
55 Neutral | $1.19B | ― | 222.83% | ― | 35.62% | 49.58% | |
51 Neutral | $7.77B | -0.12 | -39.78% | 2.21% | 22.68% | -1.42% | |
50 Neutral | $698.59M | ― | -24.75% | ― | 2190.50% | 52.85% | |
43 Neutral | $752.26M | ― | -50.67% | ― | 41.86% | 10.48% | |
42 Neutral | $1.49B | ― | -63.96% | ― | ― | -36.92% |
On February 25, 2025, Day One Biopharmaceuticals announced its financial results for the fourth quarter and full year 2024, reporting OJEMDA net product revenues of $29.0 million for Q4 and $57.2 million for the year. The company ended 2024 with $531.7 million in cash and investments, and highlighted the approval of OJEMDA as a catalyst for growth. Significant achievements included the Exclusively Pediatric designation for OJEMDA, progress in clinical trials, and increased R&D and SG&A expenses. The announcement reflects Day One’s strategic positioning for long-term growth and its commitment to advancing pediatric cancer treatments.